This product is used for nucleic acid screening of suspected patients with 2019 novel coronavirus SARS-CoV-2 virus.
Product development for early detection and surveillance in the fields of cancer,
neurodegenerative diseases, and infectious diseases
Novel tumor protein marker screening platform
Recombinant Antibody Antigen Preparation Platform
Monoclonal antibody rapid preparation platform
Exosome enrichment capture platform
A protein detection platform for tissue-specific exosomes
Novel tumor protein marker screening platform
Recombinant Antibody Antigen Preparation Platform
Monoclonal antibody rapid preparation platform
Exosome enrichment capture platform
A protein detection platform for tissue-specific exosomes
Novel tumor protein marker screening platform
Recombinant Antibody Antigen Preparation Platform
Monoclonal antibody rapid preparation platform
Exosome enrichment capture platform
A protein detection platform for tissue-specific exosomes
This product is used for nucleic acid screening of suspected patients with 2019 novel coronavirus SA
China's vaccines are included in WHO's "emergency use list", and neutralizing an
On the afternoon of February 19, 2021, Wang Anting, Director of Registration Office of Shanghai Food and Drug Administra
On the morning of January 21, 2021, Hu Huanzhong, deputy general manager of Shanghai Waigaoqiao Group Co., Ltd., led Che
A high-tech enterprise engaged in product development for early detection and monitoring in the fields of tumors, neurodegenerative diseases, and infectious diseases
Integrity and innovation, outstanding responsibility
Senior team, well-known all over the country
8 honorary certificates including high-tech enterprises
17 independent innovation patented technologies
Hotline: 021-50680557
Address: 5th Floor, Building 2, No. 271, Gangao Road,
Shanghai Pilot Free Trade Zone, China
Follow Liangrun
